In Vivo Study of Femptosecond Laser Ablation
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2005 - February 28, 2007
Grant ID
G2005021
Summary
The current procedure for reducing eye pressure is to make an opening in the trabecular meshwork to allow the aqueous humor to flow more freely into the Schlemm’s canal. A common form of this procedure is known as laser trabecular ablation, or LTA. This procedure involves long pulse durations that can cause collateral damage, including inflammation and scarring, and eventually leads to closure of the incision. Dr. Edward plans to study the results of a new technique using an ultrafast Titanium Sapphire laser, which has been found to overcome all of the aforementioned problems. By studying changes in the treated eye over a period of up to two months, Dr. Edward hopes to better understand the interplay between mechanical effects of the laser and the biologic response that might occur during wound healing.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Using AI to Detect Loss of Connections Between Neural Cells in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Luca Della Santina, PhD, PharmD
Current Organization
University of Houston
Using AI to Detect Loss of Connections Between Neural Cells in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Luca Della Santina, PhD, PharmD
Current Organization
University of Houston
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet